In the news

Using information from a number of continuous data-stream sensors in implantable cardiac devices, Boston Scientific developed the HeartLogic Heart Failure Diagnostic, which can predict heart failure events on average 34 days before they happen. The algorithm alerts doctors of worsening conditions, allowing for earlier intervention and preventative action.

Boston Scientific has put forward real-world safety data gathered on its left atrial appendage occlusion device, the WATCHMAN FLX™. The latest data from Boston Scientific, which spanned more than 16,000 patients with atrial fibrillation not caused by heart valve problems who received the next-generation WATCHMAN FLX device, demonstrated favorable outcomes.

The COVID-19 pandemic has exacerbated the opioid epidemic, and the need for a broader menu of non-opioid treatment options has never been greater. Boston Scientific continues to invest in cutting-edge therapies to help patients and their doctors navigate the ever-changing pain management journey. The Boston Scientific WaveWriter Alpha™ Spinal Cord Stimulation System provides multiple therapy options that can be used in combination to help patients find relief.

Boston Scientific has spent approximately $1 billion buying stakes in about 50 companies globally through its ventures portfolio as a source for new innovation and potential mergers and acquisitions down the road. Since 2018, half of the 16 acquisitions the company completed went through Boston Scientific Ventures, including three of five acquisition targets in 2021.

Baptist Health cardiologist Salil Patel has performed the first procedure in Northeast Florida using the SYNERGY MEGATRON™ stent during a coronary procedure to eliminate blockages in a patient’s heart. The SYNERGY MEGATRON™ is designed for use in large proximal vessels and features architecture with increased strength as well as the ability to expand to 6.0mm in diameter and accommodate tapered vessels.